1. Home
  2. QTTB vs SFHG Comparison

QTTB vs SFHG Comparison

Compare QTTB & SFHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • SFHG
  • Stock Information
  • Founded
  • QTTB 2015
  • SFHG 1993
  • Country
  • QTTB United States
  • SFHG Hong Kong
  • Employees
  • QTTB N/A
  • SFHG N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • SFHG Publishing
  • Sector
  • QTTB Health Care
  • SFHG Consumer Discretionary
  • Exchange
  • QTTB Nasdaq
  • SFHG Nasdaq
  • Market Cap
  • QTTB 18.9M
  • SFHG 18.9M
  • IPO Year
  • QTTB N/A
  • SFHG 2024
  • Fundamental
  • Price
  • QTTB $1.97
  • SFHG $0.71
  • Analyst Decision
  • QTTB Hold
  • SFHG
  • Analyst Count
  • QTTB 8
  • SFHG 0
  • Target Price
  • QTTB $24.00
  • SFHG N/A
  • AVG Volume (30 Days)
  • QTTB 227.4K
  • SFHG 58.0K
  • Earning Date
  • QTTB 08-06-2025
  • SFHG 08-29-2025
  • Dividend Yield
  • QTTB N/A
  • SFHG N/A
  • EPS Growth
  • QTTB N/A
  • SFHG N/A
  • EPS
  • QTTB N/A
  • SFHG N/A
  • Revenue
  • QTTB N/A
  • SFHG $19,760,935.00
  • Revenue This Year
  • QTTB N/A
  • SFHG N/A
  • Revenue Next Year
  • QTTB N/A
  • SFHG N/A
  • P/E Ratio
  • QTTB N/A
  • SFHG N/A
  • Revenue Growth
  • QTTB N/A
  • SFHG 30.89
  • 52 Week Low
  • QTTB $1.35
  • SFHG $0.55
  • 52 Week High
  • QTTB $53.79
  • SFHG $24.00
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 50.74
  • SFHG N/A
  • Support Level
  • QTTB $1.57
  • SFHG N/A
  • Resistance Level
  • QTTB $2.08
  • SFHG N/A
  • Average True Range (ATR)
  • QTTB 0.22
  • SFHG 0.00
  • MACD
  • QTTB -0.03
  • SFHG 0.00
  • Stochastic Oscillator
  • QTTB 53.04
  • SFHG 0.00

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About SFHG Samfine Creation Holdings Group Limited Ordinary Share

Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.

Share on Social Networks: